PostHeaderIcon Is the Obesity Epidemic Leveling Off? Don’t be Too Sure.

Recently, CDC epidemiologists published an article in the Journal of the American Medical Association to the effect that there was not a significant change over the past 12 years in the nation’s obesity rate of 35.5% for adult men and 35.8% for adult women. Many, but not all, media reports interpreted this as meaning the obesity epidemic was leveling off. But is that really the case? Let’s look behind the headlines.

First, let’s keep in mind that, even if BMI is highly correlated with body fatness, it still misses a lot of groups for whom the BMI is a crude indicator of body fatness or excess adipose tissue.

Second, obesity prevalence should not be judged by making the BMI of 30 the sole criteria. This is better explained if you look at the “etables” accompanying the article. These breakdown the categories by age and gender and graphically plot the changes in BMI from 1988 to 2010. While each graph is slightly different, they basically all show three trends: the population at normal weight is declining, the population with a BMI of 30 is getting even heavier and the BMI level for 90% of each subgroup is progressively increasing. Bottom line: fewer Americans are at a normal weight and the overweight and obese subgroups are gaining weight.

Read more...

 

PostHeaderIcon OAC & Obesity PPM Joint Press Release

Obesity Action Coalition (OAC ) Partners with Obesity PPM on Online Educational Initiative to Increase the Understanding of the Complexity of Obesity

OAC-Logo-300x173For Immediate Release

December 28th, 2011

For More Information:

James Zervios
Director of Communications
(800) 717-3117
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Tampa, Fla. – In February 2012, the OAC and Obesity PPM will launch a long-term online educational initiative to increase understanding of the complexity of obesity and its many causes. The disease of obesity impacts individuals physically, emotionally, economically and socially. This initiative will look at various factors both controllable and uncontrollable by individuals affected by obesity.

Running throughout 2012 and 2013, the initiative will take a three-pronged approach: a 14-part series of publicly available webinars, articles addressing aspects of Obesity PPM’s Twelve Pillars® model, and social media enriching the public dialogue about each event topic.  The first live, online event will take place in late January 2012.

Read more...

 

PostHeaderIcon The Twelve Pillars® Model of Obesity

Currently, our scientific community, healthcare delivery infrastructure, public and elected officials, media, and society as a whole lack consensus about the true nature of obesity.  This environment, composed of key stakeholders who lack a clear definition of the problem, has dramatically slowed collective efforts to find solutions.  Questions abound:

  • Is obesity a disease?
  • Who is accountable?
  • What is the true cost of obesity to individuals, employers, and society?
  • What are the ideal roles of public policy and government intervention?
  • What treatments and policies are effective?

Unfortunately, our only authentic point of consensus is that obesity is a legitimate public health and economic crisis in the United States and the majority of the world's developed economies. 

The Twelve Pillars® model is an etiological framework for obesity that defines and describes the complex interchange of shifting factors impacting individuals and populations. Our services and public outreach campaigns seek to clearly define the obesity problem space according to the Twelve Pillars®. Obesity PPM will make the underlying Twelve Pillars® obesity research tool, assessment instrument, and data model commercially available in the fourth quarter of 2012.

Every person suffering from obesity is, to varying degrees, impacted by each of the six individual pillars, and must successfully address each of them to maximize his or her likelihood of achieving and maintaining a healthy weight. They must also successfully navigate their environment, as defined by the six population pillars. Reversing the obesity epidemic requires careful balancing of education, personal accountability and motivation with highly-individualized and multidisciplinary clinical medicine, all in an environmental context that supports, rather than burdens, the obese. 

Read more...

 

PostHeaderIcon Unspoken: The Childhood Sexual Abuse – Obesity Connection

11/14/11 by Obesity PPM's Chief Health Policy Officer, Morgan Downey, JD

For the past week, shocking news has come out of Penn State University of alleged child sexual abuse by a former football defensive coach, Jerry Sandusky. The scandal has taken down the university’s president and its famed head coach, Joe Paterno. The school’s credit rating has been downgraded;  federal and state agencies are investigating.

Most of us react to such news with a sickening feeling of the psychological trauma the victims of such abuse, in this case including a 10 year old boy, must endure. Less well researched is the connection between child sexual abuse and adult diseases including mortality.


In 1998, Felitti et al. published a paper on the relationship of childhood abuse and household dysfunction to the leading causes of death in adults. Their study included children who were exposed to psychological, physical or sexual abuse, violence against the mother, living with household members who were substance abusers, mentally ill or suicidal or ever imprisoned. They founded a graded relationship between the number of categories of childhood exposure and adult health risk behaviors.

Read more...

 

PostHeaderIcon Is there a path forward for FDA approval of new obesity drugs?

An important artcile was published September 8th, 2011 on the topic of the challenges of FDA approval for new obesity drugs in the United States in the journal Current Opinion in Endocrinology, Diabetes and Obesity. Written by Obesity PPM's Chief Health Policy Officer Morgan Downey, researcher and scientific leader, Dr. Arya Sharma, and clinical leader at the Geisinger Obesity Institute, Dr. Chris Still, the paper is titled "Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find?"  Click here to download the PDF.  

Purpose of reviewmeridia_image_150x150
Obesity continues to increase in prevalence in the USA and throughout the world. It is clearly a major contributor to morbidity and mortality. Unfortunately, effective prevention strategies are few. As a contributor to cardiovascular disease, obesity is an important treatment objective. However, before approval, all drugs must meet safety and efficacy concerns of the US Food and Drug Administration.

Recent findings
Since July 2010, the Food and Drug Administration’s Endocrine and Metabolic Advisory Committee has reviewed three new drug applications and one previously approved drug for the treatment of obesity. This review examines in detail the Advisory Committee’sconsideration of the risk–benefit equation of the four drugs with a concentration on sibutramine and its key study, Sibutramine Cardiovascular Outcomes Trial.

Summary
Future development of drugs for the treatment of obesity will be dependent on whetherthey can survive review for safety and effectiveness. The Food and Drug Administrationcontinues to be highly concerned with proposed obesity drugs increasingcardiovascular or any risks and may require changes to clinical research protocols.KeywordsFood and Drug Administration approval, obesity, weight loss medications

 
follow us on twitter  
Obesity & Health Policy

Join the Obesity Action Coalition (OAC) and Obesity PPM on May 24th, 2012 at 8:00PM Eastern Time for the next FREE event in our two-year joint educational initiative: "Obesity & Health Policy."  

Click here to register and learn more about the event series, including the entire series schedule. 


OAC_Blue_Background

Obesity in the News
Search
follow us on twitter